Clinical trial
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II…
NCT00462423 · Lynn E. Spitler, MD, Other · Completed
Key facts
| NCT number | NCT00462423 |
|---|---|
| Title | Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study |
| Official title | Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study |
| Acronym | AbraxAvast |
| Lead sponsor | Lynn E. Spitler, MD, Other |
| Collaborators | Celgene Corporation Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Avastin, Abraxane |
| Enrollment | 50 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Jan 1, 2012 |
| First posted | Apr 19, 2007 |
| Last update posted | Jan 8, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: